早期宫颈癌前哨淋巴结导航手术的长期疗效。

IF 2.4 3区 医学 Q3 ONCOLOGY
Shinichi Togami, Nozomi Furuzono, Mika Mizuno, Shintaro Yanazume, Hiroaki Kobayashi
{"title":"早期宫颈癌前哨淋巴结导航手术的长期疗效。","authors":"Shinichi Togami, Nozomi Furuzono, Mika Mizuno, Shintaro Yanazume, Hiroaki Kobayashi","doi":"10.1007/s10147-024-02605-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node navigation surgery, which identifies the sentinel lymph node in early cervical cancers and omits systemic pelvic lymphadenectomy in cases where no lymph node metastasis is present, has recently gained attention. However, there are few reports on lymph node recurrence and the long-term outcomes of cervical cancer surgery performed using sentinel lymph node navigation surgery. In this study, we aimed to evaluate the long-term outcomes of sentinel node navigation surgery for early-stage cervical cancer.</p><p><strong>Methods: </strong>One hundred thirty-eight patients with cervical cancer were enrolled. Sentinel lymph nodes were identified by injecting 99 m Technetium-labeled phytate and indocyanine green into the uterine cervix. Surgery and survival outcomes were also analyzed.</p><p><strong>Results: </strong>The median age and body mass index of the patients were 40 years (20-78) and 21.7 kg/m<sup>2</sup> (16.5-50.4), respectively. Open surgery, laparoscopic surgery, and robotic surgery were performed in 77 (56%), 53 (38%), and 8 (6%) patients, respectively. The overall and bilateral detection rates of the sentinel lymph node were 100% and 94%, respectively. Only one case (0.7%) exhibited lower extremity lymphedema, and pelvic lymphocele was observed in three cases (2.2%). Four cases (3%) experienced recurrence over a median follow-up of 57.5 months (range, 2-115 months), with five-year recurrence-free and overall survival rates of 97% and 97.3%, respectively.</p><p><strong>Conclusions: </strong>Our results demonstrate that sentinel node navigation surgery may be safe and effective for early-stage cervical cancer.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1740-1745"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511683/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer.\",\"authors\":\"Shinichi Togami, Nozomi Furuzono, Mika Mizuno, Shintaro Yanazume, Hiroaki Kobayashi\",\"doi\":\"10.1007/s10147-024-02605-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sentinel lymph node navigation surgery, which identifies the sentinel lymph node in early cervical cancers and omits systemic pelvic lymphadenectomy in cases where no lymph node metastasis is present, has recently gained attention. However, there are few reports on lymph node recurrence and the long-term outcomes of cervical cancer surgery performed using sentinel lymph node navigation surgery. In this study, we aimed to evaluate the long-term outcomes of sentinel node navigation surgery for early-stage cervical cancer.</p><p><strong>Methods: </strong>One hundred thirty-eight patients with cervical cancer were enrolled. Sentinel lymph nodes were identified by injecting 99 m Technetium-labeled phytate and indocyanine green into the uterine cervix. Surgery and survival outcomes were also analyzed.</p><p><strong>Results: </strong>The median age and body mass index of the patients were 40 years (20-78) and 21.7 kg/m<sup>2</sup> (16.5-50.4), respectively. Open surgery, laparoscopic surgery, and robotic surgery were performed in 77 (56%), 53 (38%), and 8 (6%) patients, respectively. The overall and bilateral detection rates of the sentinel lymph node were 100% and 94%, respectively. Only one case (0.7%) exhibited lower extremity lymphedema, and pelvic lymphocele was observed in three cases (2.2%). Four cases (3%) experienced recurrence over a median follow-up of 57.5 months (range, 2-115 months), with five-year recurrence-free and overall survival rates of 97% and 97.3%, respectively.</p><p><strong>Conclusions: </strong>Our results demonstrate that sentinel node navigation surgery may be safe and effective for early-stage cervical cancer.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"1740-1745\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511683/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-024-02605-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02605-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:前哨淋巴结导航手术可确定早期宫颈癌的前哨淋巴结,并在无淋巴结转移的病例中省略全身盆腔淋巴结切除术。然而,关于使用前哨淋巴结导航手术进行宫颈癌手术的淋巴结复发和长期疗效的报道却很少。本研究旨在评估早期宫颈癌前哨淋巴结导航手术的长期疗效:方法:共纳入 138 名宫颈癌患者。方法:138 名宫颈癌患者接受了前哨淋巴结导航手术,通过向宫颈注射 99 m 锝标记的植酸和吲哚菁绿来确定前哨淋巴结。还对手术和生存结果进行了分析:患者的中位年龄和体重指数分别为 40 岁(20-78)和 21.7 kg/m2(16.5-50.4)。分别有77名(56%)、53名(38%)和8名(6%)患者接受了开腹手术、腹腔镜手术和机器人手术。前哨淋巴结的总检出率和双侧检出率分别为100%和94%。只有 1 例(0.7%)患者出现下肢淋巴水肿,3 例(2.2%)患者出现盆腔淋巴肿大。中位随访57.5个月(2-115个月),4例(3%)患者复发,五年无复发率和总生存率分别为97%和97.3%:我们的研究结果表明,前哨节点导航手术对早期宫颈癌可能是安全有效的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer.

Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer.

Background: Sentinel lymph node navigation surgery, which identifies the sentinel lymph node in early cervical cancers and omits systemic pelvic lymphadenectomy in cases where no lymph node metastasis is present, has recently gained attention. However, there are few reports on lymph node recurrence and the long-term outcomes of cervical cancer surgery performed using sentinel lymph node navigation surgery. In this study, we aimed to evaluate the long-term outcomes of sentinel node navigation surgery for early-stage cervical cancer.

Methods: One hundred thirty-eight patients with cervical cancer were enrolled. Sentinel lymph nodes were identified by injecting 99 m Technetium-labeled phytate and indocyanine green into the uterine cervix. Surgery and survival outcomes were also analyzed.

Results: The median age and body mass index of the patients were 40 years (20-78) and 21.7 kg/m2 (16.5-50.4), respectively. Open surgery, laparoscopic surgery, and robotic surgery were performed in 77 (56%), 53 (38%), and 8 (6%) patients, respectively. The overall and bilateral detection rates of the sentinel lymph node were 100% and 94%, respectively. Only one case (0.7%) exhibited lower extremity lymphedema, and pelvic lymphocele was observed in three cases (2.2%). Four cases (3%) experienced recurrence over a median follow-up of 57.5 months (range, 2-115 months), with five-year recurrence-free and overall survival rates of 97% and 97.3%, respectively.

Conclusions: Our results demonstrate that sentinel node navigation surgery may be safe and effective for early-stage cervical cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍: The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信